Voyager Therapeutics, Inc. (VYGR)

Over the past six months, Voyager Therapeutics' stock price has fluctuated, with a share price of $4.08 as of January 7, 2026, a 28.71% decline from January 8, 2025. Key events include the Third Quarter 2025 financial results, which reported a net loss of $27.9 million, a collaboration with Transition Bio to develop small molecules targeting TDP-43, and the addition of an APOE program to its pipeline. Analyst ratings have been adjusted by H.C. Wainwright and Leerink, with a consensus rating of "Moderate Buy" and an average price target of $13.75.

October historically favors a long bias for Voyager Therapeutics, Inc. The company's revenue is driven by licensing agreements and collaborative research rather than commercial product sales. Therefore, traditional demand seasonality for products and services in the consumer sense is not directly applicable at this stage of the company's development.

Voyager Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for severe neurological diseases. They design and deliver engineered AAV vectors to target cells in the brain and central nervous system, utilizing their TRACER™ AAV capsid discovery platform. Voyager's pipeline includes genetic medicines for conditions like Alzheimer's, Parkinson's, ALS, Friedreich's ataxia, and Huntington's disease, with programs advancing through partnerships with companies like Alexion, AstraZeneca, Novartis, and Neurocrine Biosciences.

Voyager Therapeutics, Inc. is headquartered in Cambridge, Massachusetts, US. The company focuses on developing treatments for global neurological diseases, but the information does not detail specific international operational or commercial geographic footprints beyond its US headquarters and partnerships with international pharmaceutical companies.

Voyager Therapeutics is known as a pioneering biotechnology company focused on gene therapy for neurological diseases. Events affecting its reputation include increased losses amid rising R&D costs, strategic collaborations and pipeline advancements, and analyst sentiment. The report of increased net losses in Q3 2025 due to higher research and development costs could be perceived negatively by some investors. Announcements of new collaborations and the addition of new programs generally enhance the company's reputation. The consensus rating of "Moderate Buy" from multiple analysts suggests a generally positive outlook.

Voyager Therapeutics, Inc. is primarily controlled by institutional investors. Major institutional owners include BlackRock, Inc., Armistice Capital, Llc, and Vanguard Group Inc. Institutional investors hold approximately 34.35% to 60.07% of the company's stock, while public/retail investors hold around 39.05% to 63.42%. Insiders hold a smaller percentage, approximately 0.88% to 2.23%.